Cargando…

The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC

ABSTRACT: Gemcitabine is considered a standard treatment for pancreatic cancer, but developing drug resistance greatly limits the effectiveness of chemotherapy and increases the rate of recurrence. Lysyl oxide-like 2 (LOXL2) is highly expressed in pancreatic cancer and is involved in carcinogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yun Sun, Kim, Hyung Sun, Kim, Hyo Jung, Kang, Hyeon Woong, Lee, Da Eun, Kim, Myeong Jin, Hong, Woosol Chris, Kim, Ju Hyun, Kim, Minsoo, Cheong, Jae-Ho, Park, Joon Seong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663195/ https://www.ncbi.nlm.nih.gov/pubmed/37737908 http://dx.doi.org/10.1007/s00109-023-02369-6

Ejemplares similares

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer
por: Kim, Myeong Jin, et al.
Publicado: (2023)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer
por: Hong, Woosol Chris, et al.
Publicado: (2023)

Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT
por: Zhang, Qing, et al.
Publicado: (2020)

Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer
por: Kang, Hyeon Woong, et al.
Publicado: (2023)

Inhibition of LOXL2 Enhances the Radiosensitivity of Castration-Resistant Prostate Cancer Cells Associated with the Reversal of the EMT Process
por: Xie, Peng, et al.
Publicado: (2019)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Emerging role of LOXL2 in the promotion of pancreas cancer metastasis
por: Park, Joon Seong, et al.
Publicado: (2016)

Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells()()
por: Lee, Yong Sang, et al.
Publicado: (2018)

Role of LOXL2 in the epithelial-mesenchymal transition and colorectal cancer metastasis
por: Park, Pil-Gu, et al.
Publicado: (2017)

Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer
por: Jung, H, et al.
Publicado: (2015)

Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Gregori, Alessandro, et al.
Publicado: (2023)

Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
por: Malinova, Antonia, et al.
Publicado: (2021)

Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma
por: Kim, Im-kyung, et al.
Publicado: (2019)

Autophagy is required for PDAC glutamine metabolism
por: Seo, Ju-Won, et al.
Publicado: (2016)

Potential association of LOXL1 with peritoneal dissemination in gastric cancer possibly via promotion of EMT
por: Hu, Qingjiang, et al.
Publicado: (2020)

Autophagy resists EMT process to maintain retinal pigment epithelium homeostasis
por: Feng, Hao, et al.
Publicado: (2019)

Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells
por: Zhao, Hengqiang, et al.
Publicado: (2017)

microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer
por: Funamizu, Naotake, et al.
Publicado: (2023)

Variations in LOXL1 associated with exfoliation glaucoma do not affect amine oxidase activity
por: Kim, Seonkwan, et al.
Publicado: (2012)

Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC
por: Kim, Min Woo, et al.
Publicado: (2021)

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
por: De Vita, Ferdinando, et al.
Publicado: (2016)

Integrating Gemcitabine-Based Therapy With AdipoRon Enhances Growth Inhibition in Human PDAC Cell Lines
por: Ragone, Angela, et al.
Publicado: (2022)

Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis
por: Choi, Yeon-Sook, et al.
Publicado: (2022)

Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights
por: Iacobazzi, Rosa Maria, et al.
Publicado: (2021)

LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-β1/Smad3/NF-κB pathway
por: Luo, Jun, et al.
Publicado: (2022)

Epigenetic regulation of TGF-β-induced EMT by JMJD3/KDM6B histone H3K27 demethylase
por: Lee, Su-Hyun, et al.
Publicado: (2021)

TGF-β induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer
por: Kim, Bit Na, et al.
Publicado: (2020)

A Theoretical Approach to Coupling the Epithelial-Mesenchymal Transition (EMT) to Extracellular Matrix (ECM) Stiffness via LOXL2
por: Deng, Youyuan, et al.
Publicado: (2021)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
por: Ding, Jinsheng, et al.
Publicado: (2021)

Loxl2 and Loxl3 Paralogues Play Redundant Roles during Mouse Development
por: Santamaría, Patricia G., et al.
Publicado: (2022)

Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2012)

EMT in immuno-resistance
por: Terry, Stéphane, et al.
Publicado: (2015)

Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells
por: Kim, Myoungjae, et al.
Publicado: (2019)

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
por: Lee, Hee Seung, et al.
Publicado: (2017)

Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway
por: Yu, Chao, et al.
Publicado: (2018)

LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Concurrent treatment with simvastatin and NF-κB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-κB/LIN28/let-7 miRNA signaling pathway
por: Kang, Minyong, et al.
Publicado: (2017)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_41fkre6t42cjms4crqcluuf3u1